Scholarlink

Background <p>Pregnancy can significantly influence seizure control and antiepileptic drug (AED) pharmacokinetics in women with epilepsy. This case–control study evaluated the impact of pregnancy on seizure frequency, AED serum levels, treatment adherence, and maternal–fetal outcomes in women with primary epilepsy.</p> Methods <p>Sixty women with primary epilepsy (30 pregnant and 30 non-pregnant) were prospectively assessed. Collected data included sociodemographic characteristics, seizure patterns, AED regimens, serum AED levels, EEG findings, and perinatal outcomes. Seizure frequency changes were monitored across pregnancy in the case group and compared with the control group.</p> Results <p>Increased seizure frequency was observed in 47% of pregnant women compared with 16.7% of controls. Pregnant women demonstrated significantly higher rates of sub-therapeutic serum levels of sodium valproate (59.1% vs. 15.8%; <i>P</i> = 0.005) and carbamazepine (26.7% vs. 0%; <i>P</i> = 0.032), while phenytoin levels showed no significant difference between groups. EEG abnormalities were detected in four cases and four controls; polyspike discharges appeared only in controls. Non-compliance with AED therapy was more frequent among pregnant women and was strongly associated with seizure exacerbation. A history of catamenial epilepsy was associated with higher, though non-significant, rates of increased seizure frequency (44.4% vs. 16.7%; <i>P</i> = 0.068) and worsening seizure severity (50.0% vs. 16.7%; <i>P</i> = 0.060). Adverse perinatal outcomes included preterm delivery (20.0%), low birth weight (16.7%), and congenital anomalies (6.7%).</p> Conclusions <p>Pregnancy is associated with an increased risk of seizure exacerbation in women with primary epilepsy, primarily due to sub-therapeutic AED levels and reduced treatment adherence. Routine therapeutic drug monitoring and targeted counseling are essential to maintaining seizure control and minimizing maternal–fetal complications. Improved access to safer, cost-effective AEDs remains a priority in resource-limited settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pregnancy and primary epilepsy: the interwoven effects on seizure dynamics, AED management, and fetal well-being”

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月19日

查看全文
  • Hosna Elshony,
  • Mostafa S. Melake,
  • Rasha Elsaadawy

摘要

Background

Pregnancy can significantly influence seizure control and antiepileptic drug (AED) pharmacokinetics in women with epilepsy. This case–control study evaluated the impact of pregnancy on seizure frequency, AED serum levels, treatment adherence, and maternal–fetal outcomes in women with primary epilepsy.

Methods

Sixty women with primary epilepsy (30 pregnant and 30 non-pregnant) were prospectively assessed. Collected data included sociodemographic characteristics, seizure patterns, AED regimens, serum AED levels, EEG findings, and perinatal outcomes. Seizure frequency changes were monitored across pregnancy in the case group and compared with the control group.

Results

Increased seizure frequency was observed in 47% of pregnant women compared with 16.7% of controls. Pregnant women demonstrated significantly higher rates of sub-therapeutic serum levels of sodium valproate (59.1% vs. 15.8%; P = 0.005) and carbamazepine (26.7% vs. 0%; P = 0.032), while phenytoin levels showed no significant difference between groups. EEG abnormalities were detected in four cases and four controls; polyspike discharges appeared only in controls. Non-compliance with AED therapy was more frequent among pregnant women and was strongly associated with seizure exacerbation. A history of catamenial epilepsy was associated with higher, though non-significant, rates of increased seizure frequency (44.4% vs. 16.7%; P = 0.068) and worsening seizure severity (50.0% vs. 16.7%; P = 0.060). Adverse perinatal outcomes included preterm delivery (20.0%), low birth weight (16.7%), and congenital anomalies (6.7%).

Conclusions

Pregnancy is associated with an increased risk of seizure exacerbation in women with primary epilepsy, primarily due to sub-therapeutic AED levels and reduced treatment adherence. Routine therapeutic drug monitoring and targeted counseling are essential to maintaining seizure control and minimizing maternal–fetal complications. Improved access to safer, cost-effective AEDs remains a priority in resource-limited settings.